Corestem Competitors and Similar CompaniesClear all

Corestem's competitors and similar companies include DeNovaMed, Kangstem Biotech, Ventus Therapeutics and Sanofi.

	Corestem Corestem (코아스템) is a biopharmaceutical company that researches and commercializes stem cell technology.	DeNovaMed DeNovaMed is a pharmaceutical company specializing in therapeutic approaches to combat bacterial infections.	Kangstem Biotech Kangstem Biotech (강스템바이오텍) is a biopharmaceutical company that focuses on blood-derived stem cell therapy.	Ventus Therapeutics Ventus Therapeutics is a company that develops small molecule therapeutics intended to target key innate immune pathways.	Sanofi Sanofi is a healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.
Founding Date	Founding Date 2003	Founding Date 2006	Founding Date 2010	Founding Date N/A	Founding Date 1994
Type	Type Public	Type Private	Type Public	Type Private	Type Public
Tags	Tags Healthcare biotech drug development life sciences pharma therapy	Tags Healthcare biotech drug development life sciences pharma therapy	Tags Healthcare biotech drug development life sciences pharma therapy	Tags Healthcare biotech drug development life sciences pharma therapy	Tags Healthcare biotech drug development life sciences pharma therapy
Locations	Locations Seongnam-si, KR HQ	Locations Halifax, CA HQ Toronto, CA	Locations KR HQ	Locations Montréal, CA HQ Waltham, US	Locations Paris, FR HQ Hydra, DZ Buenos Aires, AR Macquarie Park, AU Melbourne, AU Virginia, AU Wien, AT see more
Employees	Employees 354	Employees 6	Employees 97	Employees 952% increase	Employees 82,878
Financial
Revenue (est.)	Revenue (est.) ₩28.8b (FY, 2024)	Revenue (est.) N/A	Revenue (est.) ₩7.7b (FY, 2024)	Revenue (est.) N/A	Revenue (est.) €45.4b (FY, 2025)
Cost of goods	Cost of goods ₩25.6b (FY, 2024)	Cost of goods N/A	Cost of goods ₩838.6m (FY, 2024)	Cost of goods N/A	Cost of goods €11.6b (FY, 2025)
Gross profit	Gross profit ₩5.6b (FY, 2024)	Gross profit N/A	Gross profit ₩7.1b (FY, 2024)	Gross profit N/A	Gross profit €37.6b (FY, 2025)
Net income	Net income (₩26.3b) (FY, 2024)	Net income N/A	Net income (₩7.1b) (FY, 2024)	Net income N/A	Net income €8b (FY, 2025)
Funding
Latest funding round	Latest funding round N/A	Latest funding round $ 500k (about 14 years ago)	Latest funding round N/A	Latest funding round $ 100m (about 5 years ago)	Latest funding round N/A
Total funding raised	Total funding raised N/A	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 160m	Total funding raised $ 310m